C12.ai raises RMB 50M to advance Physical AI Scientists for drug discovery
Evidence notes
- C12.ai raised RMB 50M in a round led by Yonghua Capital, with participation from Weihao Chuangxin and individual investors.
- The funding follows deployment of Talos inside BeOne Medicines, where the system reportedly completed more than 3,000 operations over 50 days with zero errors.
- C12.ai combines molecular AI with robotic execution for drug-discovery and molecular-science workflows.
Company context
Develops AI-driven laboratory robotics systems for drug discovery and broader molecular science workflows. Its Talos system uses a general-purpose mobile robot, proprietary sensors, and a vision-language-action architecture to operate existing lab instruments without requiring major lab reconstruction. The company combines molecular AI with physical execution to close the loop between design, experiment, and analysis.